News
Stay up to date on the latest news and updates from Cohesion Bureau and our clients, while gaining valuable insights from our team of experts.
![](https://cohesionbureau.com/wp-content/uploads/2024/07/Chris-MedNous.png)
Insights
Provincialism is holding back Europe’s biotech sector
Commentary: Chris Maggos – MedNous June 2024 There’s an-often quoted story telling how Henry Kissinger complained that there was no...
07/2024
![](https://cohesionbureau.com/wp-content/uploads/2023/12/1702408571892.png)
Insights
What’s in store in 2024?
As we wind down for holiday season, it’s a great moment to look ahead and plan for potential opportunities. Biotech...
12/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Insights
We must reframe the discussion on Alzheimer’s disease
We’re at a pivot point in Alzheimer’s drug development, and we mustn’t let history slow us down
09/2023
![](https://cohesionbureau.com/wp-content/uploads/2024/06/LOGO-CROSSJECT-scaled.jpg)
Clients
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized...
07/2024
![](https://cohesionbureau.com/wp-content/uploads/2024/06/Bioxodes-Logo_Fond-transparent.png)
Clients
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
• First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company...
06/2024
![](https://cohesionbureau.com/wp-content/uploads/2024/06/LOGO-CROSSJECT-scaled.jpg)
Clients
Crossject announces publication of clinical data on ZEPIZURE® in Neurology and Therapy
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum®...
05/2024
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Clients
AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer’s Disease
May 13, 2024 PDF Version − Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active...
05/2024
![](https://cohesionbureau.com/wp-content/uploads/2024/06/LOGO-CROSSJECT-scaled.jpg)
Clients
Crossject announces highly successful closing of its €8 million rights offering
Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April...
04/2024
![](https://cohesionbureau.com/wp-content/uploads/2023/10/2023_PLSarticleGraph.png)
Insights
Biotech investment: is the oncology focus coming at the expense of areas with greater need?
Cell and gene therapies are the latest investment trend in the biotech sector. But a Cohesion Bureau analysis* by Julia Schüler...
10/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/07/mika-baumeister-Tz1k07Jl2no-unsplash-scaled-e1688753486341.jpg)
Insights
Why are European companies shy of IPOs?
Investors continue to have an appetite for equities, as shown by the robust performance of the stock markets in the...
07/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Clients
AC Immune Receives FDA Fast Track Designation For Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, To Treat Alzheimer’s Disease
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...
06/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Clients
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023 AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board...
06/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/mithra-logo.jpg)
Clients
Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman
May 29, 2023 01:30 ET| Source: Mithra Pharmaceuticals Inge Beernaert appointed President of the Compensation and Nomination Committee Jacques Galloy appointed...
05/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/Kinarus-Logo_RGB.png)
Clients
Kinarus Therapeutics signed CHF 1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
May 11, 2023 7:00 AM Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics...
05/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/vaccentis-logo.png)
Clients
Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
Zurich, Switzerland, May 3, 2023 – Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
05/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Clients
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Lausanne, Switzerland, April 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,...
04/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/04/etc-group_logo-1-1.png)
Clients
First MSCI index based Crypto ETP launched by ETC Group starts trading on XETRA
ETC Group MSCI Digital Assets Select 20 ETP (DA20) tracks performance of the top 20 digital assets, comprising around 85%...
04/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/05/ACIU_BIG.png)
Clients
AC Immune To Host Key Opinion Leader Webinar On Early Diagnosis And Prevention Of Alzheimer’s Disease
Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne, Switzerland, April 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...
04/2023
![](https://cohesionbureau.com/wp-content/uploads/2023/03/trobix-logo.jpg)
Clients
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision...
03/2023
![Chris Maggos](https://cohesionbureau.com/wp-content/uploads/2023/03/CM-headshot.png)
Insights
Have biotech stocks bottomed out?
by Chris Maggos (published in European Biotechnology, 15.11.2022) Biotechnology was dramatically rewarded in the financial markets through much of 2020...
11/2022